| Market Cap | 14.58B |
| Revenue (ttm) | 4.06B |
| Net Income (ttm) | 804.80M |
| Shares Out | n/a |
| EPS (ttm) | 0.10 |
| PE Ratio | 18.12 |
| Forward PE | 15.22 |
| Dividend | 0.22 (2.49%) |
| Ex-Dividend Date | Jun 24, 2025 |
| Volume | 152 |
| Average Volume | 1,502 |
| Open | 8.99 |
| Previous Close | 8.94 |
| Day's Range | 8.99 - 8.99 |
| 52-Week Range | 6.72 - 10.68 |
| Beta | 0.56 |
| RSI | 49.97 |
| Earnings Date | Aug 20, 2025 |
About Blueprint Medicines
China Longyuan Power Group Corporation Limited, together with its subsidiaries, generates and sells wind, coal, and photovoltaic (PV) power in the Chinese Mainland, Canada, South Africa, and Ukraine. It operates through Wind Power, Coal Power, PV Power, and All Others segments. The company designs, develops, constructs, manages, and operates wind, coal, and photovoltaic power plants. It also operates other power projects, such as tidal, biomass, and geothermal. In addition, the company is involved in the coal trading business. Further, it manuf... [Read more]
Financial Performance
In 2024, CLPXY's revenue was 31.37 billion, an increase of 5.87% compared to the previous year's 29.63 billion. Earnings were 6.38 billion, an increase of 1.97%.
Financial StatementsNews
China Resources Power shares dive 5.8% after US$502 million placement
Meanwhile, rival China Longyuan Power gains after deal to buy wind-farm assets from controlling stakeholder.